PRPO Precipio, Inc.

Nasdaq precipiodx.com


$ 25.98 $ -0.63 (-2.4 %)    

Thursday, 20-Nov-2025 15:47:07 EST
QQQ $ 586.53 $ -14.20 (-2.37 %)
DIA $ 458.63 $ -3.66 (-0.79 %)
SPY $ 653.48 $ -10.10 (-1.52 %)
TLT $ 89.27 $ 0.35 (0.39 %)
GLD $ 374.83 $ -0.11 (-0.03 %)
$ 25.62
$ 26.75
$ 25.22 x 2
$ 26.84 x 100
$ 27.26 - $ 28.50
$ 3.90 - $ 28.50
29,625
na
45.99M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-29-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-30-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-29-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-27-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-16-2019 03-31-2019 10-Q
28 04-16-2019 12-31-2018 10-K
29 11-19-2018 09-30-2018 10-Q
30 08-16-2018 06-30-2018 10-Q
31 05-21-2018 03-31-2018 10-Q
32 04-13-2018 12-31-2017 10-K
33 11-20-2017 09-30-2017 10-Q
34 08-22-2017 06-30-2017 10-Q
35 05-18-2017 03-31-2017 10-Q
36 04-13-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-23-2016 03-31-2016 10-Q
40 04-14-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 precipio-terminates-sales-agreement-with-agp

-SEC Filing

 precipio-q2-eps-005-up-from-083-yoy-sales-5654m-up-from-4441m-yoy

Precipio (NASDAQ:PRPO) reported quarterly earnings of $0.05 per share. This is a 106.02 percent increase over losses of $(0.83)...

 precipio-revises-warrant-agreement-with-largest-holder-100k-to-be-exercised-for-cash-200k-through-cashless-conversion

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has entered into an agreement with its largest warrant holder...

 precipio-q4-adj-ebitda-400k
Precipio Q4 Adj. EBITDA $400K
02/25/2025 14:30:54

 precipio-announces-the-launch-of-a-new-version-of-its-bloodhound-mpn-panel-that-is-now-able-to-distinguish-between-calr-type-1-and-type-2-mutations

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the launch of a new version of its Bloodhound MPN (...

 precipio-reports-03m-cash-generated-by-operations-in-q2-2024

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated fr...

 precipio-reports-q2-2024-revenue-of-44m-vs-433m-est-expects-pathology-divisions-revenues-will-reach-more-than-15m-per-month-by-year-end

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grow...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION